

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

**RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON AUGUST 30, 2024**

The Board is pleased to announce that all the Resolutions set out in the Notice were duly passed by way of poll by the Shareholders at the AGM held on August 30, 2024

References are made to (i) the notice of the annual general meeting (the “**AGM**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated July 30, 2024 (the “**Notice**”); and (ii) the circular of the Company dated July 30, 2024 (the “**Circular**”). Capitalized terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

RESULTS OF THE AGM

The board of directors (the “**Director**”) of the Company (the “**Board**”) is pleased to announce that at the AGM held at Plum-Seeking Grove Conference Room, VIP Meeting Room 802, Visitor Center, Area C, Alibaba Xixi Campus, No. 960–1, West Wen Yi Road, Yu Hang District, Hangzhou, China on Friday, August 30, 2024 at 10:30 a.m., all

the resolutions set out in the Notice (the “**Resolutions**”) were duly passed by way of poll by the shareholders of the Company (the “**Shareholders**”). The poll results in respect of the Resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		Number of Shares Voted (Approximate %)	
		For	Against
1	To receive, consider and adopt the audited consolidated financial statements of the Group and the reports of the directors and auditor for the year ended March 31, 2024.	12,085,259,030 (99.99%)	942,040 (0.01%)
2	To re-elect the following retiring Directors:		
	(a) Mr. Xu Haipeng as a non-executive Director;	11,935,145,788 (98.75%)	151,055,042 (1.25%)
	(b) Ms. Huang Yi Fei (Vanessa) as an independent non-executive Director;	12,083,862,900 (99.98%)	2,338,185 (0.02%)
	(c) Dr. Shao Rong as an independent non-executive Director; and	12,083,710,181 (99.98%)	2,490,773 (0.02%)
	(d) Ms. Wu May Yihong as an independent non-executive Director.	11,905,952,140 (98.51%)	180,248,821 (1.49%)
3	To authorize the Board to fix the Directors’ remuneration.	12,085,254,997 (99.99%)	729,197 (0.01%)
4	To re-appoint Ernst & Young as the auditor of the Company and to authorize the Board to fix its remuneration.	12,041,353,479 (99.63%)	44,843,279 (0.37%)
5	To grant a general mandate to the Directors to issue and allot Shares.	11,263,179,264 (93.19%)	823,017,755 (6.81%)
6	To grant a general mandate to the Directors to repurchase Shares.	12,082,084,756 (99.97%)	4,112,263 (0.03%)
7	To approve the addition of the aggregate amount of Shares repurchased as mentioned in ordinary resolution no. 6 to the aggregate amount that may be issued and allotted pursuant to ordinary resolution no. 5.	11,425,066,804 (94.53%)	661,130,084 (5.47%)

ORDINARY RESOLUTIONS		Number of Shares Voted (Approximate %)	
		For	Against
8	(a) To approve the proposed adoption of a share award scheme of the Company (the “ 2024 Share Award Scheme ”), details of which are set out in the section headed “Letter from the Board — Proposed Adoption of the 2024 Share Award Scheme and Termination of the 2014 Share Award Scheme” in the Circular;	11,289,397,894 (93.41%)	796,803,060 (6.59%)
	(b) To approve and adopt the Scheme Mandate Limit (as defined in the 2024 Share Award Scheme) on the total number of shares that may be issued (and, together with treasury shares which may be transferred, as applicable) in respect of all options and awards to be granted to the eligible participants under the 2024 Share Award Scheme and all the share schemes of the Company, being ten (10)% of the issued shares (excluding treasury shares) of the Company as at the date of the AGM; and	11,288,534,470 (93.40%)	797,666,615 (6.60%)
	(c) To approve and adopt the Service Provider Sublimit (as defined in the 2024 Share Award Scheme) on the total number of shares that may be issued (and, together with treasury shares which may be transferred, as applicable) in respect of all options and awards to be granted to eligible participants who are service providers under the 2024 Share Award Scheme and all the share schemes of the Company, being one (1)% of the issued shares (excluding treasury shares) of the Company as at the date of the AGM.	11,288,534,587 (93.40%)	797,666,498 (6.60%)
9	Subject to and conditional upon the passing of the ordinary resolution no.8, to approve the proposed termination of the 2014 Share Award Scheme (as defined in the Circular) upon the 2024 Share Award Scheme becoming adopted (after the fulfilment of all the conditions as set out in the 2024 Share Award Scheme).	11,507,435,073 (95.21%)	578,766,012 (4.79%)

SPECIAL RESOLUTION		Number of Shares Voted (Approximate %)	
		For	Against
10	To approve the proposed amendments to the bye-laws of the Company, details of which are set out in the section headed “APPENDIX III — PROPOSED AMENDMENTS TO THE BYE-LAWS” in the Circular.	12,082,200,301 (99.97%)	4,000,653 (0.03%)

Notes:

- (1) The full text of the Resolutions is set out in the Notice.
- (2) To the best knowledge, belief and information of the Directors, as at the date of the AGM:
 - (a) the total number of Shares in issue was 16,091,736,264;
 - (b) the Trustee held 735,924 and 15,708,751 Shares for the CP Trust Account and the NCP Trust Account, respectively, representing approximately 0.005% and 0.098% of the issued share capital of the Company, respectively. The Trustee is required to abstain, and has abstained, from voting on all of the Resolutions at the AGM;
 - (c) the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions at the AGM was 16,075,291,589;
 - (d) the total number of Shares entitling the Shareholders to attend and vote only against the Resolutions at the AGM was nil; and
 - (e) save as disclosed, there were no Shares entitling the holder to attend and abstain from voting in favour of the Resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), no Shareholders were required under the Listing Rules to abstain from voting on the Resolutions, and there were no Shareholders that had stated their intention in the Circular to vote against or abstain from voting in respect of any Resolutions proposed at the AGM.
- (3) The Directors that attended the AGM were Mr. Zhu Shunyan, Mr. Shen Difan, Mr. Tu Yanwu, Ms. Huang Jiaojiao, Mr. Xu Haipeng, Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong.
- (4) Tricor Secretaries Limited, the Company’s branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the AGM for the purpose of vote-taking in respect of the Resolutions.

As more than 50% of the total votes were cast in favour of each of Resolutions no. 1 to no. 9, these Resolutions were duly passed as ordinary resolutions of the Company.

As more than 75% of the total votes were cast in favour of Resolution no. 10, Resolution no. 10 was duly passed as a special resolution of the Company.

By Order of the Board
Alibaba Health Information Technology Limited
Shen Difan
Chief Executive Officer

Hong Kong, August 30, 2024

As at the date of this announcement, the Board comprises Mr. Zhu Shunyan, Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Ms. Huang Jiaojiao as the non-executive Director; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.